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Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) is a childhood malignancy, typically occurring in the
bone and rarely in any other part of the body. We herein present a case of ES/PNET of the renal pelvis. A 37-year-old
male patient presented with a chief complaint of pain in the left flank and gross hematuria. The tumor had caused
moderate hydronephrosis, and ureteroscopic biopsy findings were highly suspicious of sarcoma. Subsequently, radical
nephroureterectomy was performed. On the basis of the pathological and cytogenetic findings, a final diagnosis of
primary ES/PNET of left renal pelvis was made. Adjuvant chemotherapy with adriamycin and ifosfamide was initiated as
ES/PNET often exhibits aggressive biological behavior. The patient was disease-free at his last regular follow-up visit
18 months after the surgery. To our knowledge, this is the first reported case of primary ES/PNET of the renal pelvis.
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Ewing sarcoma/primitive neuroectodermal tumor (ES/
PNET) is the second most common form of bone malig-
nancy (after osteosarcoma) occurring in childhood [1].
However, ES/PNET of extra-skeletal origin is an ex-
tremely rare entity. With the exception of ES/PNET aris-
ing from the renal parenchyma, ES/PNET of the renal
pelvis has never been reported in the literature. To help
establish the biological nature of primary ES/PNET of
the renal pelvis, we present the clinical, diagnostic, and
therapeutic aspects of this rare neoplasm along with a
review of the literature.Case presentation
A 37-year-old male patient was admitted with a chief
complaint of intermittent pain in the left plank and
gross hematuria. His past medical history and findings
of a physical examination were unremarkable. Results of
his blood chemistry and routine blood tests were within
the normal range. Urine cytology showed no signs of ma-
lignancy. Ultrasonography demonstrated a 4-cm hypoe-
choic mass occupying the dilated left renal pelvis, the* Correspondence: yipinglu@163.com
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reproduction in any medium, provided the orpresence of which was subsequently confirmed by en-
hanced computed tomography (CT) (Figure 1) and left
retrograde pyelography. Cytology of the washout fluid
obtained from the retrograde catheterization was also
negative for malignancy. Further clinical investigations
showed no evidence of metastasis. A preoperative ure-
teroscopic biopsy performed, with findings highly suspi-
cious of sarcoma. The patient subsequently underwent
open, left radical nephroureterectomy with excision of the
bladder cuff. No intraoperative or postoperative complica-
tions developed.
Macroscopic examination showed that a 4.0 × 2.3 ×
1.5 cm soft tissue mass was situated in the renal pelvis,
with lobulated contours, a gray-white cut surface, and
an intact renal parenchyma. Microscopic examination
revealed a small round cell tumor with focal necrosis, in-
filtrating the smooth muscle layer of the renal pelvis and
without renal parenchyma involvement. On immunohis-
tochemistry, the tumor cells stained positive for CD99
(Figure 2), CD56, S-100, and vimentin; focally positive
for epithelial membrane antigen and Ki-67; and negative
for Bcl-2, cytokeratin 7, cytokeratin 20, desmin, WT-1,
muscle specific actin, and Syn. On the basis of these find-
ings, a pathological diagnosis of primary ES/PNET of the
left renal pelvis was made. The diagnosis was further con-
firmed by fluorescence in situ hybridization (FISH) toThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Contrast-enhanced CT demonstrating a 4-cm soft-tissue mass occupying the dilated left renal pelvis. (A) Enhanced CT. (B) Left
retrograde pyelography.
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vant chemotherapy with adriamycin and ifosfamide
was administered as ES/PNET often exhibit highly ag-
gressive biological behavior. The patient was in excel-
lent physical and mental condition without recurrence or
metastasis as confirmed by careful follow-up at 18 months
postoperatively.
Conclusion
During the past two decades, nine cases of primary sar-
coma of the renal pelvis have been described in the English
literature: six of leiomyosarcoma, two of rhabdomyosar-
coma, and one of cystic embryonal sarcoma (Table 1)
[2-10]. To our knowledge, this is the first case of primary
ES/PNET of the renal pelvis to be reported in the litera-
ture. Although being a rare entity, sarcoma should be in-
cluded in the preoperative differential diagnosis of renal
pelvis tumors. However, preoperative diagnosis of sarcoma
is often difficult because of its rare incidence, non-specific
clinical presentation, and radiological features (similar to
those of urothelial carcinoma). Tsai et al. [8] and ChowFigure 2 Immunohistochemistry showed intense positive
membranous CD99 staining.et al. [9] reported the use of fine-needle aspiration bi-
opsy with good results for primary renal pelvis sarcoma.
Furthermore, for tumors of the upper urinary tract, ure-
teroscopic biopsy may be useful in establishing a more ac-
curate preoperative diagnosis and deciding on the surgical
modality, as was performed in the case reported here.
Histologically, lymphoblastic lymphoma, neuroblast-
oma, rhabdomyosarcoma, poorly differentiated synovial
sarcoma, and Wilms tumor are included in the differen-
tial diagnosis of ES/PNET because they are all small
round cell tumors. High levels of universal membranous
CD99 expression are seen in ES/PNET cells, but this is
not specific for ES/PNET. Thus, a broad immunohisto-
chemistry panel may aid in differentiating these unique
entities, even though this is sometimes difficult. Recently,
molecular techniques have been increasingly used to con-
firm the diagnosis of ES/PNET, as it is one of the few solid
tumors for which underlying chromosomal translocations
have been described [11]. The most common transloca-
tion is the t(11, 22) (q24; q12), detected in more than 85%
of ES/PNET by FISH or reverse transcription-polymerase
chain reaction. Accurate diagnosis is essential, as these tu-
mors require different treatment strategies.
As ES/PNET rarely spreads to lymph nodes, the single
most important factor considered when planning initial
treatment is the extent of disease at presentation, with the
lungs being the most common site of metastasis. Initial
presentation is the main factor that influences prognosis.
The 5-year survival rate associated with extraskeletal ES/
PNET in adults is 60% and 33% for non-metastatic and
metastatic disease [1,12], respectively. Surgical resection
may be the treatment of choice for local control in ES/
PNET. However, ES/PNET often results in rapid recur-
rence or metastasis, even after complete resection. There-
fore, patients with ES/PNET may require multidisciplinary
management, combining systemic neoadjuvant and/or ad-
juvant chemotherapy with local control measures (surgery
and/or radiation). Ifosfamide-based protocols appear to
Table 1 Sarcoma of the renal pelvis reported in the English literature during the past two decades [2-10]
First author/Year Age (yr)/Sex Symptoms & signs Side Size
(cm)
Therapy Histological subtype Follow-up
Chow 1994 56/F Abdominal distension R 15 RN, thromb-ectomy Leiomyosarcoma 2 yr/DOM
Ito 2000 12/M Abdominal pain, massive bleeding R NA SN Cystic embryonal sarcoma 26 yr/NED
Moudouni 2001 41/M Flank pain, gross hematuria L 2 RNU Leiomyosarcoma 8 yr/NED
Kren 2003 49/F Flank pain R 1.8 RNU Rhabdomyo-sarcoma 2 yr/NED
Minami 2004 54/M Bowel discomfort L 8 RN Leiomyosarcoma 6 mo/NED
Kartsanis 2006 44/M Gross hematuria L 5 RNU, PL Leiomyosarcoma 3 yr/NED
Tsai 2006 77/F Gross hematuria, voiding difficulty,
flank tenderness
R 2 RN Rhabdomyo-sarcoma 5 mo/Alive
Chung 2007 42/F Asymptomatic L 5 RN Leiomyosarcoma NA
Dhamne 2009 60/M Urinary frequency, weakness,
weight loss
R 10 RN Leiomyosarcoma 6 mo/NED
Our case 2012 37/M Flank pain, gross hematuria L 4 RNU, chemo-therapy Ewing’s sarcoma 4 yr/NED
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Novel molecular-targeted therapies for the treatment of
ES/PNET have now transitioned from the laboratory to
the clinical setting. In a recent phase I trial of a fully hu-
man IgG2 monoclonal antibody targeting the insulin-like
growth-factor-1 receptor, figitumumab, a number of pa-
tients with refractory, advanced ES/PNET responded un-
expectedly well [14]. Such patients should be informed
about relevant clinical trials and encouraged to enter these
trials. Due to the rarity of this condition, the impact of dif-
ferent treatment modalities (simple nephrectomy vs. rad-
ical nephrectomy vs. radical nephroureterectomy with or
without chemotherapy and/or radiotherapy) on outcomes
cannot be evaluated until more cases have been reported.
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